Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Cervantes F, Hernández-Boluda JC, Odriozola J, Camós M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J, Montserrat E. Cervantes F, et al. Br J Haematol. 2003 Feb;120(3):500-4. doi: 10.1046/j.1365-2141.2003.04077.x. Br J Haematol. 2003. PMID: 12580969 Free article. Clinical Trial.
Modern management of myelofibrosis.
Cervantes F. Cervantes F. Br J Haematol. 2005 Mar;128(5):583-92. doi: 10.1111/j.1365-2141.2004.05301.x. Br J Haematol. 2005. PMID: 15725078 Free article. Review.
Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Granell M, Vallansot R, Besses C, Montserrat E. Cervantes F, et al. Br J Haematol. 2006 Jul;134(2):184-6. doi: 10.1111/j.1365-2141.2006.06142.x. Epub 2006 Jun 1. Br J Haematol. 2006. PMID: 16740139 Free article. Clinical Trial.
Myelofibrosis: biology and treatment options.
Cervantes F. Cervantes F. Eur J Haematol Suppl. 2007 Oct;(68):13-7. doi: 10.1111/j.1600-0609.2007.00937.x. Eur J Haematol Suppl. 2007. PMID: 17727559 Review. No abstract available.
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F. Hernández-Boluda JC, et al. Among authors: cervantes f. Eur J Haematol. 2017 Apr;98(4):407-414. doi: 10.1111/ejh.12846. Epub 2017 Jan 19. Eur J Haematol. 2017. PMID: 28009442 Clinical Trial.
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.
Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Luño E, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares M, Mata-Vázquez MI, Regadera A, Pereira A, Cervantes F; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Among authors: cervantes f. Br J Haematol. 2018 May;181(3):397-400. doi: 10.1111/bjh.14601. Epub 2017 Apr 17. Br J Haematol. 2018. PMID: 28419426 Free article. No abstract available.
545 results